Long term shareholders are growing weary, there is a limit to...

First 11 Last

Share
Profile

Follow
absolutely clueless

1,201 Posts.

114

02/09/16

08:31

Post #: 18876435
Share

Originally posted by w27 ↑

Nadolol has an application way beyond smoking cessation. We have had a trial in mild asthma paid for by the USA National Institute of Health. This seems to have dropped off the radar and we are still awaiting final results. I have always believed that the simple fact that the NIH was prepared to finance this whole programme was serious endorsement of this drug as a treatment for asthma. There is a serious unmet need in asthma treatment and the market for a successful drug is huge.
However the real pot of gold is the inhaled drug to treat COPD, asthma, cystic fibrosis and other respiratory conditions. This market is huge and as far as I can find out, there is nothing else on the horizon. Smoking cessation is mostly an early route to market. It is a side show in the over-all potential.

Expand

Long term shareholders are growing weary, there is a limit to how many times posters can regurgitate the science. Why has a deal been so difficult? Dr Collier said in March 2015 the reason for the 2.5c capital raise was to finalize data for a possible sale or out licence in 6 months. Anybody have any idea?... patent exclusivity with 3M? Skinny labelling concerns? Asking too much ? Dr Glass said at the 2014 AGM 'watch this space', well we all have been. Time for a deal.

IVX Price at posting: 0.4¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply